ZA201906696B - Liquid formulation of anti-tnf alpha antibody - Google Patents

Liquid formulation of anti-tnf alpha antibody

Info

Publication number
ZA201906696B
ZA201906696B ZA2019/06696A ZA201906696A ZA201906696B ZA 201906696 B ZA201906696 B ZA 201906696B ZA 2019/06696 A ZA2019/06696 A ZA 2019/06696A ZA 201906696 A ZA201906696 A ZA 201906696A ZA 201906696 B ZA201906696 B ZA 201906696B
Authority
ZA
South Africa
Prior art keywords
liquid formulation
tnf alpha
alpha antibody
antibody
tnf
Prior art date
Application number
ZA2019/06696A
Inventor
So Ra Yun
Youn Kyung Ko
Jineon So
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63522490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201906696(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of ZA201906696B publication Critical patent/ZA201906696B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ZA2019/06696A 2017-03-16 2019-10-10 Liquid formulation of anti-tnf alpha antibody ZA201906696B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170033188 2017-03-16
PCT/KR2018/003097 WO2018169348A1 (en) 2017-03-16 2018-03-16 Liquid formulation of anti-tnf alpha antibody

Publications (1)

Publication Number Publication Date
ZA201906696B true ZA201906696B (en) 2020-08-26

Family

ID=63522490

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/06696A ZA201906696B (en) 2017-03-16 2019-10-10 Liquid formulation of anti-tnf alpha antibody

Country Status (15)

Country Link
JP (2) JP7109849B2 (en)
KR (2) KR20180106974A (en)
CN (1) CN110621303A (en)
AU (1) AU2018236651B2 (en)
BR (1) BR112019019162A2 (en)
CO (1) CO2019010860A2 (en)
MA (1) MA46988A1 (en)
MX (1) MX2019010895A (en)
MY (1) MY197202A (en)
NZ (1) NZ757965A (en)
PH (1) PH12019502075A1 (en)
RU (1) RU2756619C2 (en)
UA (1) UA123847C2 (en)
WO (1) WO2018169348A1 (en)
ZA (1) ZA201906696B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20210435A (en) 2019-02-18 2021-09-20 Lilly Co Eli Therapeutic antibody formulation
TW202102260A (en) * 2019-03-21 2021-01-16 美商再生元醫藥公司 Stabilized formulations containing anti-il-33 antibodies
WO2021164717A1 (en) * 2020-02-20 2021-08-26 百奥泰生物制药股份有限公司 ANTI-TNF-α ANTIBODY PREPARATION, PREPARATION METHOD THEREFOR AND USE THEREOF

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140186361A1 (en) * 2012-09-07 2014-07-03 Coherus Biosciences, Inc. Stable Aqueous Formulations of Adalimumab
TWI603739B (en) * 2010-11-11 2017-11-01 艾伯維生物技術有限責任公司 Improved high concentration anti-tnfα antibody liquid formulations
UY34105A (en) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd STABLE LIQUID FORMULATION OF ETANERCEPT
MX363700B (en) * 2012-03-07 2019-03-29 Cadila Healthcare Ltd Pharmaceutical formulations of tnf-alpha antibodies.
BR112015017619A2 (en) * 2013-01-24 2017-11-21 Glaxosmithkline Ip Dev Ltd liquid formulation, use of a formulation, and kit
JP2016515515A (en) * 2013-03-15 2016-05-30 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ Anti-prolactin receptor antibody preparation
WO2015134406A1 (en) * 2014-03-03 2015-09-11 La Jolla Biologics, Inc. Stable aqueous recombinant protein formulations
CA2944330A1 (en) * 2014-04-02 2015-10-08 Intas Pharmaceuticals Limited Liquid pharmaceutical composition of adalimumab
PT2946765T (en) * 2014-05-23 2016-11-10 Ares Trading Sa Liquid pharmaceutical composition
US9821059B2 (en) * 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
HUP1400510A1 (en) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Pharmaceutical anti-tnfalpha antibody formulation
UY36542A (en) * 2015-01-28 2016-08-31 Mabxience S A PHARMACEUTICAL FORMULATIONS FOR ANTI-TNF-ALFA ANTIBODIES
WO2016162819A1 (en) * 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody

Also Published As

Publication number Publication date
UA123847C2 (en) 2021-06-09
JP2020510079A (en) 2020-04-02
KR102342292B1 (en) 2021-12-24
RU2756619C2 (en) 2021-10-04
WO2018169348A1 (en) 2018-09-20
JP2022097600A (en) 2022-06-30
NZ757965A (en) 2022-07-01
PH12019502075A1 (en) 2020-09-14
AU2018236651B2 (en) 2020-12-10
CN110621303A (en) 2019-12-27
JP7109849B2 (en) 2022-08-01
RU2019130728A3 (en) 2021-04-16
CO2019010860A2 (en) 2020-01-17
RU2019130728A (en) 2021-04-16
MX2019010895A (en) 2019-11-05
MY197202A (en) 2023-05-31
KR20180106974A (en) 2018-10-01
BR112019019162A2 (en) 2020-04-14
KR20200096472A (en) 2020-08-12
MA46988A1 (en) 2020-06-30
AU2018236651A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
IL282962A (en) Anti-pd-1 antibodies and methods of use thereof
HK1244492A1 (en) Anti-pd-1 antibodies and methods of use thereof
CL2016003250A1 (en) Monoclonal antibodies against the epitope of her2 and its methods of use
HUE062927T2 (en) Anti-tigit antibodies and methods of use thereof
HUE062436T2 (en) Anti-trem2 antibodies and methods of use thereof
SG11201705585QA (en) Anti-myostatin antibodies and methods of use
SG11201706505PA (en) Stable liquid formulation for monoclonal antibodies
HK1251969A1 (en) Anti-her2 antibodies and methods of use
HK1254743A1 (en) Novel anti-claudin antibodies and methods of use
HK1259251A1 (en) Humanized anti-c1s antibodies and methods of use thereof
IL286208A (en) Humanized influenza monoclonal antibodies and methods of use thereof
IL268731A (en) New uses of anti-sirpg antibodies
EP3394098A4 (en) Anti-myostatin antibodies and methods of use
IL265438A (en) Chimeric antigen receptors and compositions and methods of use thereof
PL3110447T3 (en) Anti-egfr antibody and uses of same
SG11202001720RA (en) Liquid dosage forms of imatinib
ZA201906696B (en) Liquid formulation of anti-tnf alpha antibody
ZA201805051B (en) Egfl6 specific monoclonal antibodies and methods of their use
HUE059831T2 (en) Application of liquids
IL274221A (en) Anti-apoc3 antibodies and methods of use thereof
GB2548424B (en) Liquid pharmaceutical composition of clonidine